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ScienceDirectPatient-derived xenografts (PDXs) are obtained by
transplanting fragments of a patient’s tumour into
immunodeficient mice. Growth and propagation of PDXs
allows correlating therapeutic response in vivo with extensive,
multi-dimensional molecular annotation, leading to
identification of predictive biomarkers. PDXs are increasingly
recognised as clinically relevant models of cancer for several
reasons, of which the main is the possibility of studying the
behaviour of cancer cells in a natural microenvironment, where
they interact with stromal components accrued from the mouse
host. PDXs maintain close similarities with the tumour of origin,
in terms of tissue architecture, molecular features and
response to treatments. Indeed, preclinical trials in PDXs have
been shown to match and also anticipate data obtained in
patients. Exploration of more complex processes like
metastatic evolution and antitumour immune responses is
actively pursued with PDXs, as new generations of host models
emerge on the horizon.
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Introduction
Development of experimental models that correctly reca-
pitulate tumour biology, genetic heterogeneity and drug
response has been a key objective of cancer research since
its inception. PDXs are generated by implanting patient-
derived tumour tissue into host animal models, typically
immunocompromised mice. After a first step of engraft-
ment and adaptation to the new host, PDX tumours can
be grown, explanted, aliquoted and implanted in further
animals, a process known as ‘passage’, to generate cohortswww.sciencedirect.com of animals hosting the same tumour, for preclinical treat-
ment efficacy studies (Figure 1). PDX-derived tumour
tissue can also be cryopreserved, to generate of a ‘living
tissue biobank’ for virtually unlimited tissue availability
for experiments and molecular profiling. The main advan-
tage of PDXs versus in vitro cancer cell cultures is the
possibility of studying cancer cells in their microenviron-
ment and assessing the involvement of fibroblasts, endo-
thelial cells and leukocytes in tumour biology and
response to treatments. Over many years, PDXs have
been used to study multiple aspects of the neoplastic
disease [1]. The PDX field is in continuous expansion,
and large consortia like EurOPDX in Europe (URL:
http://www.europdx.eu/) and PDXNet in the USA
(URL: https://www.pdxnetwork.org/) have been estab-
lished to standardise procedures and make PDXs avail-
able to the cancer research community. In this review, we
summarise the most recent findings derived from the use
of PDXs as cancer models.
Modelling drug response and resistance
Patient-derived xenografts (PDXs) are widely used to
recapitulate how the complexity of tumour biology affects
drug response. In the last few years, several studies have
been conducted to define pharmacological vulnerabil-
ities. In this context, a large-scale in vivo screen in
1000 PDX models assessed the value of such approach
in term of reproducibility and clinical translatability, to
identify associations between genotypes and drug
responses [2]. As an alternative to using large PDX
cohorts to establish genotype-response correlations, a
more empirical strategy is based on the ‘Avatar’ approach:
an individual patient’s tumour tissue is used to derive
PDXs, on which multiple treatments are tested, so that
the most effective can be administered to the patient of
origin. PDXs can be used to investigate personalised
treatments in real-time (co-clinical trials), as well as to
find and validate new targets [3,4]. PDX-based studies
allowed optimisation of clinical trial designs, providing
strong rationale for new combinatorial regimens in
patients refractory to conventional treatments [5,6].
PDX models have been employed to recapitulate mech-
anisms of primary and acquired drug resistance [7,8]. In
vivo studies highlighted that tumour resistance mecha-
nisms identified in PDXs are also found in the original
patient samples resistant to target therapy. This provided
potential treatment options in resistant tumours [9] and
the proof of concept for the heterogeneous nature ofCurrent Opinion in Biotechnology 2020, 63:151–156
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Generation, expansion and use of PDXs. The patient-derived tumour is implanted into an immunodeficient mouse and, after the engraftment
phase, it is explanted and expanded in multiple passages, enabling the generation of cohorts of PDXs, suitable for preclinical «xenotrials» to
evaluate drug efficacy. PDX-derived tumour samples can be collected at every passage to create a frozen, vital tissue biobank and to perform
molecular profiles and ex vivo experiments.acquired resistance [10]. A limitation of the PDX
approach is the considerable effort and time required
to test in vivo the response to multiple drugs. To over-
come this issue, in vivo implantable devices allow testing
simultaneously different drugs in adjacent regions of the
same PDX tumour [11]. Moreover, loss-of-function
genetics screenings have been exploited to identify
new therapeutic targets, employing pooled short hairpin
RNA (shRNA) libraries, adapted for in vivo screens in cell
line xenografts and PDXs [12].
PDX-derived in vitro models
In vivo experiments in PDXs are limited by cost, size,
time and resources. Reaching the adequate sample size to
explore inter-patient heterogeneity is therefore quite
challenging. The use of in vitro tests on PDX-derived
cells followed by in vivo validation is a valid alternative
and can be achieved in different ways. Short-term 2D
cultures can be used for rapid drug tests, that displayed
good concordance with in vivo experiments [13]. Alter-
natively, long-term cultures may be employed to estab-
lish cell lines retaining the properties of the PDX of origin
[14]. Patient-derived or PDX-derived cells can be grown
as 3D organoids [15], that retain certain architectural
features and can be used for drug efficacy studies and also
to further generate PDXs when direct in vivo propagationCurrent Opinion in Biotechnology 2020, 63:151–156 is limiting [16,17]. Cancer-initiating stem cells can be
derived from PDXs and maintained in suspension as
spheroids, a good model for studying the biology and
drug sensitivity of cancer stem cells [18].
Modelling tumour-stroma interactions
It is widely recognised that the biology of solid tumours
depends on the ability of cancer cells to recruit and
educate vascular, mesenchymal and immune cells, that
collectively form the tumour microenvironment, or
tumour stroma. During engraftment in a PDX, cancer
cells retain this ability, so that while the tumour grows
human stromal cells are replaced by mouse counterparts,
thus providing an ideal experimental model to character-
ise tumour-stroma interactions [19]. Indeed, the fact that
stromal cells in a PDX are of mouse origin has been
considered a limit, potentially affecting tumour biology
and evolution [20]. However, the histological architecture
of the tumour tissue is maintained during PDX propaga-
tion, suggesting that the key mediators of tumor-stroma
interactions are functional [21]. Moreover, proteomic
analyses revealed high correspondence of matched
tumour and PDX stromal profiles, as well as adaptation
of the stromal proteome upon PDX engraftment, with
distinct profiles for different PDX samples [22,23].www.sciencedirect.com
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sively explored as potential therapeutic targets, we
report here the most recent findings. In colorectal
cancer (CRC) PDXs harbouring APC mutations, block-
ade of the RSPO3 signal from cancer-associated fibro-
blasts (CAFs) to cancer cells enhanced the activity of
paclitaxel-based chemotherapy [24]. Prolonged treat-
ment of lung cancer xenografts with a kinase inhibitor
induced a metabolic shift toward increased lactate pro-
duction in cancer cells, that in turn induced a paracrine
supply of HGF from CAFs, promoting resistance. This
adaptive resistance mechanism was also observed in
patients, which showed clinical relevance [25]. In
CRC PDXs, non-canonical TGF-beta signalling from
cancer cells was found to activate CAFs. Inhibition of
this axis led to reduction of metastatic dissemination
and increased sensitivity to therapy [26]. Finally, in
breast cancer PDXs, microvesicle-mediated transfer of
miR-221 from CAFs to cancer cells was found to pro-
mote resistance to hormonal therapy, highlighting a new
therapeutic avenue [27].
Modelling metastasis
The possibility of modelling metastatic progression using
subcutaneous PDX implants is quite limited. However, a
much bettermimic of this process is obtainedby implanting
PDXs in the same tissue from which the patient’s tumour
was explanted [28]. This type of implant, called orthotopic,
in most cases requires microsurgical competences and in
vivo imaging, for the implant [29] and for subsequent
evaluation ofprimary tumourandmetastases development.
A notable exception is breast cancer, for which the standard
PDX implant in the mammary fat pad is intrinsically
orthotopic and allows modelling metastasis [30].
Several approaches have been developed and exploited to
study the metastatic process and its therapeutically
actionable dependencies in PDXs. The most straightfor-
ward is the implant of the primary tumour in the corre-
sponding site of the mouse. Metastatic behaviour can be
further enhanced when stromal cells are added to cancer
cells [31]. When the source material is limited (e.g.
metastasis biopsies), a first generation of PDXs can be
derived subcutaneously, and then implanted orthotopi-
cally, retaining the features of the tumour of origin,
including metastatic ability [17]. Human metastases have
been implanted orthotopically in the primary tumour site,
to model at the same time tumour growth at the primary
site and metastatic propagation [32]. Finally, human
metastases can be implanted in the primary metastasis
site, as in the case of liver-metastatic CRC, to recapitulate
the behaviour of the disease within its metastatic micro-
environment [33]. It is worth noting that in all these cases
morphological, molecular and pharmacological features of
the orthotopic PDXs correctly recapitulated those of the
tumour of origin.www.sciencedirect.com Modelling anticancer immunotherapy
To avoid rejection of human tumour implants, PDXs are
invariably generated in immunocompromised mice. Var-
ious mouse strains have been developed over several
decades with progressively increasing immunosuppres-
sion, from athymic nude mice in 1966 to non-obese
diabetic-severe combined immunodeficiency (NOD-
SCID) mice in 1995, to NOD-SCID-Gamma-null
(NSG) in 2002. Higher levels of immunodeficiency allow
better engrafting [34], but also progressively reduce the
possibility to explore the role of the immune system in
tumour biology and response to treatments [35]. This
drawback is particularly critical for modelling immuno-
therapy based on checkpoint inhibitors, as it requires an
intact human immune system. A way to overcome this
limitation is the generation of ‘humanized’ mouse mod-
els, by engrafting NSG mice with human leukocytes or
hematopoietic stem cells. Patient tumour tissues are then
engrafted into the humanized mice and used for studying
the efficacy of immunomodulatory treatments. However,
this approach has a high risk of graft-versus-host disease
and therefore allows only short term experiments [36,37].
Mouse ‘humanization’ has been improved by genetically
inserting human cytokine genes (M-CSF, IL-3,GM-CSF
thrombopoietin) at their respective mouse loci, plus
transgenic expression of human SIRPa28 which enables
mouse phagocytes to tolerate human cells [38]. Indeed,
recent studies with humanized mouse PDXs have pro-
vided significant advances in the comprehension of can-
cer immunotherapy [39,40].
Conventional PDXs can still have a good use for modelling
another type of immunotherapy, called ‘adoptive
immunotherapy’, in which cytotoxic T-lymphocytes, nat-
ural killer cells or engineered killer cells are administered to
test their direct anticancer activity. As an example, Jesper-
sen and colleagues inserted melanoma tumour cells and T
cells from the same patient into NSG mice and showed
tumour inhibition [41]. Alternatively, cytokine-induced
killer (CIK) cells can be generated from the patient or from
donors and tested for anticancer efficacy in PDX, alone or in
combination with cancer-targeting antibodies [42]. An
interesting research frontier in adoptive immunotherapy
is the engineering of killer cells with a chimeric antigen
receptor, to direct them against a specific antigen expressed
by cancer cells. Also this approach has been successfully
validated in PDX models [43,44].
PDXs for biomarker development
The fact that PDXs provide a virtually unlimited source
of tumour tissue for multi-dimensional molecular profiles
and allow testing response to multiple drugs in the same
model opened a new avenue for biomarker discovery.
Moreover, the fact that DNA and RNA from stromal cells
are of mouse origin enables distinguishing cancer cell-
intrinsic (human) from microenvironmental (mouse)
molecular profiles without the need for microdissectionCurrent Opinion in Biotechnology 2020, 63:151–156
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based biomarker discovery include: (i) identification of
lung cancer cell-specific downregulation of histocompati-
bility antigens, further confirmed in clinical samples and
associated to resistance to immunotherapy [46]; (ii) lack of
GATA4 expression as a predictor of sensitivity to
TGFBR1 inhibition [47]; (iii) identification of p38-alpha
inhibition as sensitizer to taxanes in breast cancer [48].
PDXs have also been used to study circulating tumour
cells (CTCs). In breast cancer, a molecular signature
associated with the presence of CTC clusters in PDXs
was associated with worse outcome in patients [49]. The
possibility of performing species-specific RNA sequenc-
ing of PDXs to distinguish cancer cell from stromal
transcriptomes has been extensively exploited in CRC,
leading to the identification on one side of a poor prog-
nosis stromal signature [45], and on the other of cancer-
cell-intrinsic molecular subtypes of CRC (CRIS sub-
types) with unprecedented predictive and prognostic
power [50,51]. Similarly, a cancer cell-intrinsic microsat-
ellite instability transcriptional signature defined in gas-
tric cancer PDXs was found to identify patients with
worse prognosis [52].
Conclusion and outlook
PDXs offer unprecedented opportunities for developing
precision medicine approaches to cancer treatment. Vast
PDX collections have been generated globally, summing
up to thousands of cases and enabling population-scale
preclinical trials that capture inter-tumour heterogeneity.
Yet, each individual model recapitulates within itself the
complexity of a single human tumour, allowing in-depth,
longitudinal exploration of adaptive and evolutive dynam-
ics that typically confer resistance to treatments. The PDX
community is facing important challenges to improve the
efficacy of these models. In particular, the time, effort and
costs necessary for in vivo experiments are urging research-
ers to develop and use ex vivo systems, exploiting PDX-
derived cells for simpler in vitro experiments before
embarking in PDX tests. Improved ways of modelling
metastatic progression and interactions between cancer
and its microenvironment are continuously being devel-
oped, as well as in-depth molecular profiling of all tumour
components. The time in which newly diagnosed cancer
patients will find existing PDXs with matching features for
treatment personalization is not far.
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Bruna A, Budinská E, Caldas C, Chang DK et al.: Interrogating
open issues in cancer medicine with patient-derived
xenografts. Nat Rev Cancer 2017, 17:632.
2. Gao H, Korn JM, Ferretti S, Monahan JE, Wang Y, Singh M,
Zhang C, Schnell C, Yang G, Zhang Y et al.: High-throughput
screening using patient-derived tumor xenografts to predict
clinical trial drug response. Nat Med 2015, 21:1318-1325.
3. Savaikar MA, Whitehead T, Roy S, Strong L, Fettig N, Prmeau T,
Luo J, Li S, Wahl RL, Shoghi KI: SUV(25) and mPERCIST:
precision imaging of response to therapy in co-clinical FDG-
PET imaging of triple negative breast cancer (TNBC) patient-
derived tumor xenografts (PDX). J Nucl Med 2019. pii:
jnumed.119.234286. [Epub ahead of print].
4.

Inoue A, Deem AK, Kopetz S, Heffernan TP, Draetta GF, Carugo A:
Current and future horizons of patient-derived xenograft
models in colorectal cancer translational research. Cancers
(Basel) 2019, 11 pii: E1321
This review provides information on ongoing co-clinical trials to evaluate
the utility of PDX models in predicting drug response in various primary
and metastatic solid tumours beyond CRC.
5. Bertotti A, Migliardi G, Galimi F, Sassi F, Torti D, Isella C, Corà D, Di
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